` CPHRF (Cipher Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

CPHRF
vs
S&P 500

Over the past 12 months, CPHRF has underperformed S&P 500, delivering a return of +11% compared to the S&P 500's +15% growth.

Stocks Performance
CPHRF vs S&P 500

Loading
CPHRF
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CPHRF vs S&P 500

Loading
CPHRF
S&P 500
Difference
www.alphaspread.com

Performance By Year
CPHRF vs S&P 500

Loading
CPHRF
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Cipher Pharmaceuticals Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Cipher Pharmaceuticals Inc
Glance View

Market Cap
278.8m USD
Industry
Pharmaceuticals

Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. The company is headquartered in Oakville, Ontario. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products directly in Canada and indirectly through partners in the United States, Canada and South America. Its Dermatology products include Actikerall, Epuris, Ozanex, and Vaniqa. Its Hospital Acute Care products are Aggrastat and Brinavess. The Company’s Out-Licensed Products include Absorica, ConZip, Durela, and Lipofen. The company is focused on three strategy that includes acquisitions, in-licensing, and selective investments in drug development to assemble a portfolio of prescription products that serve unmet medical needs. The firm's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC and Cipher Pharmaceuticals US LLC.

CPHRF Intrinsic Value
12.36 USD
Undervaluation 12%
Intrinsic Value
Price
Back to Top